High Antigenicity of Intraperitoneal Insulin Infusion via Implantable Devices: Preliminary Rat Studies

Intraperitoneal insulin infusion of Genapol° stabilized insulin via implantable devices significantly improves diabetes control and hypoglycemia frequency in type1 diabetes while it increases insulin antibody levels. Causes for this particular antigenicity remain unknown.

The role of insulin modifications occurring in the reservoir on the antigenicity observed was assessed by comparing the antigenicities of the insulin coming from the vial or from the pump reservoir.

Rats were injected intraperitoneally with insulin sampled either from a vial (group 1) or from a pump reservoir during a refill of a clinical trial (group 2). Two control groups, one without insulin, the second one receiving a mixture of silicone and insulin were also studied. Human insulin antibody levels were assessed by RIA 10 days after 4 weekly immunizations. AIA levels were higher in group 1 compared to group 2 (P = 0.003 for the first experiment, P = 0.04 in the second experiment). The increased antigenicity of the insulin sampled from the implanted pump might be due to the insulin modifications occurring during the storage in the device. Insulin aggregates could be involved in this antigenicity since they are known to be antigenic and their concentration was shown to be related to the amplitude of the antigenic response.

- Insulin Antibodies - Insulin Stability - Insulin Aggregates - Type 1 Diabetes Mellitus- Insulin Therapy

References

• 1 Jeandidier N, Boivin S. Current status and future prospects of parenteral insulin regimens, strategies and delivery systems for diabetes treatment.  Advanced Drug Delivery Reviews. 1999;  35 179-198
• 2 Broussole C, Jeandidier N, Hanaire H. French multicenter experience of implantable insulin pumps.  Lancet. 1994;  343 514-515
• 3 Olsen C, Chan E, Turner D, Iravani M, Nagy M, Selam J L, Wong N, Waxman K, Charles A. Insulin antibody responses after longterm intraperitoneal insulin administration via implantable programmable insulin delivery systems.  Diabetes Care. 1994;  17 169-176
• 4 Lassmann-Vague V, Belicar P, Raccah D, Vialettes B, Sodoyez J C, Vague P h. Immunogenicity of long term intraperitoneal insulin administration with implantable pumps: metabolic consequences.  Diabetes Care. 1995;  18 498-503
• 5 Jeandidier N, Boivin S, Sapin R, Rosart-Ortega F, Uring Lambert B, Réville P h, Pinget M. Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices.  Diabetologia. 1995;  38 577-584
• 6 Schernthaner G. Immunogenicity and allergic potential of animal and human insulin.  Diabetes Care. 1993;  16 155-165
• 7 Overkamp D, Mohammed Ali S, Cartledge C, Landon. Production of polyclonal antibodies in ascitic fluid of mice: technic and applications.  J Immunoassay. 1988;  9 51-68
• 8 Buchwald H, Rohde T. International study group for implantable infusion devices 1996. The world’s only implantable infusion pump society.  ASAIO. 1997;  43 132-136
• 9 Grau U. Chemical stability of insulin in a delivery system environment.  Diabetologia. 1985;  28 458-463
• 10 Pinget M, Jeandidier N. Long term safety and efficacy of intraperitoneal insulin infusion by means of implantable pumps.  Horm Metab Res. 1998;  30 475-486
• 11 Renard E, Bouteleau S, Jacques-Apostol D, Lauton D, Gibert-Boulet F, Costalat G, Bringer J, Jaffiol C. Insulin underdelivery from implanted pumps using peritoneal route. Determinant role of insulin pump compatibility.  Diabetes Care. 1996;  19 812-827
• 12 Grau U, Saudek C. Stable insulin preparation for implanted insulin pumps, laboratory and animals trials.  Diabetes. 1987;  36 1453-1459
• 13 Van Antwerp W P, Muller W, Hagen J J, Lord P, Chambers C. Improved insulin for implantable pump therapy.  Horm. Metab Res. 1997;  29 A11(Abstract)
• 14 Broutin H, Broussolle C, Jeandidier N, Renard E, Guerci B, Haardt M J, Lassmann-Vague V. Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in IDDM. A multicenter study.  Diabetes Care. 1995;  18 388-392
• 15 Saudek C, Selam J L, Pitt H, Waxman K, Rubio M, Jeandidier N, Turner D, Fischell R, Charles A. A preliminary trial of the programmable implantable medication system for insulin delivery.  N Engl J Med. 1989;  321 574-9
• 16 Kasama T, Iwata Y, Oshiro K, Ushida M, Sakaguchi Y, Namie K, Sugiura M. Antigenicity of desamido-insulin and monocomponent insulin.  Diabetologia. 1983;  21 65-69
• 17 Robbins D, Cooper S, Fineberg E, Mead P. Antibodies to covalent aggregates of insulin in blood of insulin-using diabetic patients.  Diabetes. 1987;  36 838-841
• 18 Kurtz A, Nabarro J DN. Circulating Insulin - binding antibodies.  Diabetologia. 1980;  19 329-334
• 19 Brange J, Andersen L, Laursen E D, Meyn G, Rasmussen E. Toward understanding insulin fibrillation.  Journal of Pharmaceutical Sciences. 1997;  86 517-525
• 20 Jeandidier N, Boullu S, Delatte E, Sapin R, Friess P h, Le Galudec V, Pinget M. Comparison of the antigenicity of Hoechst 21PH insulin administered intraperitoneally or subcutaneously in type 1 diabetic patients.  Acta Diabetologica. 1999;  35 240 (Abstract)
• 21 Naim J O, Ippolito K M, van Oss C J. Adjuvancy effect of different types of silicone gel.  Journal of Biomedical Materials Reseach.. 1997;  37 534-538
• 22 Roitt I. In: Pradel (ed). Immunologie. Editions Pradel (18 rue St Denis Paris 75 001 France). Publisher Joure 1989; p. 122. 
• 23 Arquila E, Finn J. Genetic difference in antobody production to determinants groups on insulin.  Science. 1963;  142 400-401
• 24 Balsells M, Corcoy R, Mauricio D, Morales J, Garcia-Patterson A, Carreras G, Puig-Domingo M, de Leiva A. Insulin antibody response to a short course of human insulin therapy in women with gestational diabetes.  Diabetes Care. 1997;  20 1172-1174
• 25 Reeves W G, Barr D, Douglas C A, Gelsthorpe K, Hanning I, Skene A, Wells L, Wilson R M, Tattersall R B. Factors governing human immune response to injected insulin.  Diabetologia. 1984;  26 266-271
• 26 Duckworth W, Saudek C, Giobbie-Hurder A, Henderson W, et al. The Veterans Affairs implantable insulin pump study. Effects on cardiovascular risk factors.  Diabetes Care. 1998;  21 1596-1602
• 27 Neubauer H P, Schöne H H. The immunogenicity of different insulins in several animal species.  Diabetes . 1978;  27 8-15
• 28 Boivin S, Steibel J, Sapin R, Karsten V, Pinget M, Jeandidier N. Causes for the high antigenicity of intraperitoneal administration of Hoechst 21PH (U400) insulin when used in implantable pumps; preliminary results.  Horm Metab Res. 1998;  30 A8 (abstract)